BXC Form 3: Christina M. Corley Identified as Director; No Securities Owned
Rhea-AI Filing Summary
Christina M. Corley filed an initial Form 3 reporting her relationship to BlueLinx Holdings Inc. (BXC) as a director and the statement of the triggering event date of 09/22/2025. The filing explicitly states no securities are beneficially owned by the reporting person. The form includes an exhibit (Exhibit 24 Power of Attorney) and is signed by an attorney-in-fact for Ms. Corley on 09/30/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director filed initial ownership form and reported no beneficial ownership of issuer securities.
The filing is routine: an initial Form 3 identifies Christina M. Corley as a director of BlueLinx Holdings Inc. and records the event date as 09/22/2025. Importantly, the form states no securities are beneficially owned, which means there is no disclosure of shares, options, or other equity positions by the reporting person at filing. The inclusion of Exhibit 24 (Power of Attorney) and the attorney-in-fact signature are procedural and confirm authorized filing. This disclosure has limited immediate market impact because it reports absence of ownership rather than a material acquisition or disposition.
TL;DR: Compliance-focused initial filing shows no reportable holdings; procedural power-of-attorney used to sign.
From a compliance perspective, the Form 3 satisfies Section 16 reporting requirements by identifying the reporting person, relationship to the issuer (director), and the triggering date. The explicit statement that no securities are beneficially owned should be noted by regulators and the issuer as a valid initial disclosure. The attorney-in-fact signature (Christin Lumpkin) and Exhibit 24 documentation appear to support proper authorization of the filing. There are no schedules of holdings or derivative positions disclosed.
FAQ
What did Christina M. Corley report on the Form 3 for BlueLinx (BXC)?
What is the event date listed on the Form 3 for BXC?
Was the Form 3 signed and by whom for the BXC filing?
Does the filing disclose any derivative securities or options for BXC?
Is there any exhibit attached to the Form 3 for BlueLinx?